January 20, 2021 08:09 AM ESTUpdated 09:05 AM

The IPO flood keeps rising with 4 more biotechs and a SPAC on their way to Nasdaq

Max Gelman

Senior Editor

Nicole DeFeudis

Editor

After a record year for biotech IPOs in 2020, forecasts were bullish on another strong year showing for public offerings — and 2021 hasn’t disappointed so …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

The IPO flood keeps rising with 4 more biotechs and a SPAC on their way to Nasdaq

Max Gelman

Senior Editor

Nicole DeFeudis

Editor

Sign up to read this article for free.

Among pharma CEOs, the IRA now and the IRA later get very different reactions

Bristol Myers restarts radiopharmaceutical Phase 3 trial, but delays readout by one year

Andrew Left, short seller who campaigned against Valeant, is accused of fraud by SEC

Updated: With cost-cutting underway, Bristol Myers raises guidance, touts Phase 3 win and scraps another

European drug regulator rejects Alzheimer's drug Leqembi, citing safety concerns

Critical Junctures in Gene Therapy Clinical Material Manufacturing: Where Do I Start? And Will It Work?

The IPO flood keeps ris­ing with 4 more biotechs and a SPAC on their way to Nas­daq

Senior Editor

Editor

Sign up to read this article for free.

The IPO flood keeps rising with 4 more biotechs and a SPAC on their way to Nasdaq